"You need to plant many seeds – and many types - to ensure that you ultimately create a bountiful field of potential therapies. You cannot only plant one genre, or use only a single method; it's not a viable approach to drug discovery." That's how Evotec AG CEO Werner Lanthaler sums up his diversified biotech's approach, as one of its seedlings partnered with Sanofi reached a development milestone.
Sowing Seeds In Drug Discovery The Evotec Way: CEO Werner Lanthaler
Evotec's hybrid drug discovery model continues to attract pharma partners and generate internal assets using what its CEO calls a "diversified seed sowing" business approach.
More from Strategy
More from Business
• By
The US FDA approved anti-CD19 antibody Uplizna, from Amgen’s $27.8bn purchase of Horizon in 2023, for IgG4-related disease – a larger market than its original NMOSD indication.
• By
BeiGene’s Phase III ociperlimab joins the list of failed TIGIT inhibitors, as candidates from Roche, Merck & Co. and others have failed late-stage studies.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.